Results of U.S. News & World Report’s first “Best OTC Medicine & Health Products” survey include homeopathic formulations, supplements and non-drug topicals in same categories of indications with nonprescription pharmaceuticals.

Renue By Science agrees with National Advertising Division recommendations to “clearly and conspicuously disclose” material connections in online advertising by employees, nonprofits and others offering sales to its supplements containing nicotinamide mononucleotide, quercetin or resveratrol.

Approval likely would account for all weight on scale of FDA decision if not for self-report element in design of HRA Pharma’s actual use study for OTC switch of 0.075-mg norgestrel branded Opill. HRA’s sNDA offers lesson for using electronic diary apps in self-report studies.

Appropriations Agriculture, Rural Development, FDA and Related Agencies Subcommittee marked up its FY2024 bill on 18 May, proposing $6.579bn for FDA. Total is up from current budget of $6.562bn, but Biden administration proposed $7.2bn for FY2024.

"Our eyes are more on Advil, Tylenol. We want to be considered first-line treatment for pain, for pain appropriate for what our products are," says Hisamitsu America CEO John Incledon.

HBW Insight catches up with US executive editor, Malcolm Spicer, to discuss Perrigo subsidiary HRA Pharma’s Rx-to-OTC switch application for its daily contraceptive, Opill. With the switch currently under consideration by the US Food and Drug Administration after a positive recommendation from its advisory committees, Spicer draws on his in depth coverage of the subject, as well as his extensive experience writing about the US consumer health market, to tell listeners what they need to know about this historic switch.